Views:0 Author:Site Editor Publish Time: 2021-01-11 Origin:Site
The US FDA has approved the expansion of two dosing regimens (once a week and twice a week) including the combined use of dexamethasone (DKd) for the treatment of relapsed or refractory multiple myeloma ( R/R-MM) Patients who have received 1-3 courses of treatment. In the treatment of refractory myeloma with these two drugs, their respective research results have shown the effectiveness of this drug.
Multiple myeloma is a blood cancer characterized by remission and recurrence. The prognosis of patients with each relapse worsens.With the increasing use of first-line immunomodulatory drug therapies, the number of patients treated with these drugs may increase over time. “This has created a demand for effective treatment options for recurrence. "Despite the continuous progress in the treatment of multiple myeloma, this disease is still incurable. It is especially challenging for patients who relapse or are difficult to cure with existing treatments. "Director of Clinical Research of Hematology Malignant Tumor, Doctor of Medicine in Plasma Cell Diseases said. Professor of Clinical Medicine, "As clinicians, choosing this program means that we can now combine two effective targeted drugs in a new immunomodulatory drug-free triple therapy, which has proven to have a deep and lasting effect on relapsed patients. Reaction."
Betadex sulfobtuyl ether sodium (SBEBCD, CAS 182410-00-0) is a derivative of β-CD, with a negatively charged side chain, has a special effect on positively charged drugs, hydrophobic drugs The inclusion can improve the water solubility of the drug itself, and at the same time can increase the absorption of the drug in the human body and improve the stability.
In addition, it can be well included with drug molecules to form non-covalent complexes, thereby improving drug safety, reducing nephrotoxicity, alleviating drug hemolysis, controlling drug release rate, and masking unpleasant odors. Betadex sulfobtuyl ether sodium (SBEBCD, CAS 182410-00-0) has been applied to injection medicine, oral medicine, nasal medicine, eye medicine, and has special affinity and inclusion properties for nitrogen-containing drugs.